Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.
The human parainfluenza viruses (hPIVs) and respiratory syncytial viruses (RSVs) are the leading causes of hospitalizations due to respiratory viral disease in infants and young children, but no vaccines are yet available. Here we describe the use of recombinant Sendai viruses (rSeVs) as candidate vaccine vectors for these respiratory viruses in a cotton rat model. Two new Sendai virus (SeV)-based hPIV-2 vaccine constructs were generated by inserting the fusion (F) gene or the hemagglutinin-neuraminidase (HN) gene from hPIV-2 into the rSeV genome. The inoculation of either vaccine into cotton rats elicited neutralizing antibodies toward both homologous and heterologous hPIV-2 virus isolates. The vaccines elicited robust and durable antibodies toward hPIV-2, and cotton rats immunized with individual or mixed vaccines were fully protected against hPIV-2 infections of the lower respiratory tract. The immune responses toward a single inoculation with rSeV vaccines were long-lasting and cotton rats were protected against viral challenge for as long as 11 months after vaccination. One inoculation with a mixture of the hPIV-2-HN-expressing construct and two additional rSeVs (expressing the F protein of RSV and the HN protein of hPIV-3) resulted in protection against challenge viruses hPIV-1, hPIV-2, hPIV-3, and RSV. Results identify SeV vectors as promising vaccine candidates for four different paramyxoviruses, each responsible for serious respiratory infections in children.
Jones
Bart
B
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, United States.
Zhan
Xiaoyan
X
Mishin
Vasiliy
V
Slobod
Karen S
KS
Surman
Sherri
S
Russell
Charles J
CJ
Portner
Allen
A
Hurwitz
Julia L
JL
D000818:Animals; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D009500:Neutralization Tests; D022241:Parainfluenza Vaccines / Q000627:therapeutic use*; D010222:Parainfluenza Virus 1, Human / Q000276:immunology*; D010223:Parainfluenza Virus 2, Human / Q000276:immunology*; D010224:Parainfluenza Virus 3, Human / Q000276:immunology*; D018184:Paramyxoviridae Infections / Q000276:immunology* / Q000517:prevention & control*; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology* / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology*; D029082:Sendai virus / Q000235:genetics*; D016205:Sigmodontinae; D014614:Vaccines, Synthetic / Q000276:immunology
D022241:Parainfluenza Vaccines; D014614:Vaccines, Synthetic